relevance health CAO Ronald Penczek sells shares worth $183,902

Published 11/03/2025, 21:24
relevance health CAO Ronald Penczek sells shares worth $183,902

Ronald W. Penczek, Chief Accounting Officer and Controller at Elevance Health, Inc. (NYSE:ELV), a prominent healthcare provider with a market capitalization of $96 billion and "GREAT" financial health according to InvestingPro, recently sold 443 shares of the company’s common stock. The transaction, executed on March 10, 2025, was completed at a price of $415.13 per share, resulting in a total sale value of $183,902. Following this transaction, Penczek holds 1,847 shares in the company. The stock, which has maintained dividend payments for 15 consecutive years and trades at a P/E ratio of 16.3, currently appears undervalued according to InvestingPro’s Fair Value model. Discover 8 more exclusive insights about ELV with InvestingPro.

In other recent news, Elevance Health has confirmed its earnings forecast for 2025, projecting adjusted earnings per share between $34.15 and $34.85. This announcement aligns with the company’s previous expectations for Medicare Advantage membership, which is anticipated to range from 2.2 million to 2.25 million members by the end of 2025. Additionally, Elevance Health is under scrutiny as part of a broader industry concern following a DOJ investigation into Medicare billing practices at UnitedHealth Group (NYSE:UNH), though no direct accusations have been made against Elevance.

Cantor Fitzgerald has maintained an Overweight rating for Elevance Health, setting a price target of $485, while highlighting the company’s exposure to Medicaid policy changes. In contrast, JPMorgan has reduced its price target for Elevance to $479, citing a mixed outlook from recent earnings reports and challenges in the Medicaid segment. However, JPMorgan notes potential growth in Elevance’s Carelon segment and anticipates margin improvements in Medicaid due to state rate updates.

The healthcare sector has seen fluctuations, with Elevance Health experiencing a 2.2% rise in stock following President Trump’s supportive comments on social programs like Medicare and Medicaid. These developments reflect a complex landscape for Elevance Health, where regulatory scrutiny, policy changes, and financial forecasts are key factors for investors to consider.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.